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ABSTRACT
Background: Previously, a HPLC method for the determination of N-terminal prolyl 
dipeptides, proline and hydroxyproline in urine with ß uorescence detection after pre-column 
derivatization with 4-(5,6-dimethoxy-2-phthalimidinyl)-2-methoxyphenylsulfonyl chloride 
(DMS-Cl) was developed to study the relation between those analytes and bone diseases. 
When the urinary analytes were measured, a large peak due to an unknown substance was 
recognized in the chromatograms of cancer patients with metastatic bone disease, although it 
was scarcely present in normal subjects. In this study, we identiÞ ed the unknown substance.
Methods: The fluorescent fraction based on the unknown substance was collected using 
HPLC and the tructure of the ß uorescence product was analyzed with MS, 
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Results: The ß uorescence product based on the unknown substance was established to be a 
DMS-derivative of N-ethylglycine.
Conclusions: Excretion of N-ethylglycine in the urine of cancer patients with metastatic bone 
disease is recognized, although N-ethylglycine is scarcely excreted in the urine of normal 
subjects.
஢ᇩ̛шҁѳќѠ 4-(5,6-ҫӔһҠҪ -2-ӈҲӞҗӒҾҫӞ )-2-ӔһҠҪӈҚҾӞҬӞ
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